These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10176783)

  • 1. On valuing morbidity, cost-effectiveness analysis, and being rude.
    Kenkel D
    J Health Econ; 1997 Dec; 16(6):749-57. PubMed ID: 10176783
    [No Abstract]   [Full Text] [Related]  

  • 2. Introducing quality into cost effectiveness.
    Cohen DR
    Qual Assur Health Care; 1990; 2(3-4):313-9. PubMed ID: 1983251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation in health care: is there a role for cost-benefit analysis?
    Johannesson M; Jönsson B
    Health Policy; 1991 Feb; 17(1):1-23. PubMed ID: 10113574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The time trade-off: a note on the effect of lifetime reallocation of consumption and discounting.
    Dolan P; Jones-Lee M
    J Health Econ; 1997 Dec; 16(6):731-9. PubMed ID: 10176781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. A response to Sculpher and Gafni.
    Robinson A; Parkin D
    Health Econ; 2002 Oct; 11(7):649-51; discussion 653-4. PubMed ID: 12369065
    [No Abstract]   [Full Text] [Related]  

  • 6. The contingent valuation controversy in environmental economics and its relevance to health services research.
    Johannesson M
    J Health Serv Res Policy; 1996 Apr; 1(2):116-7. PubMed ID: 10180850
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of the use of health status measures in economic evaluation.
    Brazier J; Deverill M; Green C; Harper R; Booth A
    Health Technol Assess; 1999; 3(9):i-iv, 1-164. PubMed ID: 10392311
    [No Abstract]   [Full Text] [Related]  

  • 8. A proposal to solve the comparability problem in cost-utility analysis.
    Bleichrodt H; Herrero C; Pinto JL
    J Health Econ; 2002 May; 21(3):397-403. PubMed ID: 12022265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian estimation of cost-effectiveness ratios from clinical trials.
    Heitjan DF; Moskowitz AJ; Whang W
    Health Econ; 1999 May; 8(3):191-201. PubMed ID: 10348414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valuing morbidity: an integration of the willingness-to-pay and health-status index literatures.
    Johnson FR; Fries EE; Banzhaf HS
    J Health Econ; 1997 Dec; 16(6):641-65. PubMed ID: 10176777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness. How should it be determined?
    Beaves RG; Joseph H; Rohrer JE; Zeitler RR
    Eval Health Prof; 1988 Jun; 11(2):213-30. PubMed ID: 10312609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contingent valuation method in health care. An economic evaluation of Alzheimer's disease.
    Nocera S; Telser H; Bonato D
    Dev Health Econ Public Policy; 2003; 8():iii-xi, 1-116. PubMed ID: 15027158
    [No Abstract]   [Full Text] [Related]  

  • 13. Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis.
    Sculpher M; Gafni A
    Health Econ; 2001 Jun; 10(4):317-24. PubMed ID: 11400254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A note on the depreciation of the societal perspective in economic evaluation of health care.
    Johannesson M
    Health Policy; 1995 Jul; 33(1):59-66. PubMed ID: 10143700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine.
    Mandelblatt JS; Fryback DG; Weinstein MC; Russell LB; Gold MR
    J Gen Intern Med; 1997 Sep; 12(9):551-8. PubMed ID: 9294789
    [No Abstract]   [Full Text] [Related]  

  • 16. On the discounting of gained life-years in cost-effectiveness analysis.
    Johannesson M
    Int J Technol Assess Health Care; 1992; 8(2):359-64. PubMed ID: 1628916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constant and decreasing timing aversion for saving lives.
    Cairns J; van der Pol M
    Soc Sci Med; 1997 Dec; 45(11):1653-9. PubMed ID: 9428085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Willingness-to-pay (WTP): the new-old kid on the economic evaluation block.
    Gafni A
    Can J Nurs Res; 2001 Jun; 33(1):59-64. PubMed ID: 11928155
    [No Abstract]   [Full Text] [Related]  

  • 19. Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs.
    Gafni A
    Med Care; 1991 Dec; 29(12):1246-52. PubMed ID: 1745082
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness analysis in heart disease, Part I: General principles.
    Kupersmith J; Holmes-Rovner M; Hogan A; Rovner D; Gardiner J
    Prog Cardiovasc Dis; 1994; 37(3):161-84. PubMed ID: 7972851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.